ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
Decoding the Cardiac Immune Microenvironment and Fibroblast Crosstalk in Radiotherapy Combined with Immunotherapy-Induced Cardiac Fibrosis Based on Single-Cell Transcriptomic Analysis.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Bazedoxifene Attenuates Isoproterenol-Induced Cardiac Fibroblast Activation and Fibrotic Phenotype via Modulation of the IL-6/STAT3 Signaling Axis.Current issues in molecular biology · 2026Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
purposeThe combination of radiotherapy and immunotherapy (radioimmunotherapy) shows promising antitumor efficacy but raises cardiotoxicity concerns. The underlying mechanisms remain unclear.
methodsPreclinical models were used to assess cardiac function at day 28, 3 months, and 5 months post radioimmunotherapy intervention. The scRNA-seq and molecular experiments were conducted. IL-6 knockout mice and tocilizumab (IL-6R inhibitor) were used for targeted interventions.
resultsRadioimmunotherapy exacerbated cardiac fibrosis and enhanced fibroblast-immune cell crosstalk, accompanied by robust activation of IL-6 signaling predominantly derived from fibroblasts. Elevated serum IL-6 levels were also observed in patients receiving combined thoracic radiotherapy and immunotherapy. Both IL-6 knockout and tocilizumab treatment effectively alleviated acute cardiac injury, inflammation, and fibrosis. Notably, tocilizumab likely inhibits the IL-6
conclusionsOur study identifies fibroblast-immune cell interactions, particularly IL-6-mediated fibroblast-macrophage crosstalk, as a key mechanism in radioimmunotherapy-induced cardiac fibrosis. Tocilizumab, an IL-6R inhibitor, demonstrates therapeutic potential to attenuate this cardiotoxicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.